The US approved a revolutionary drug for scurvy

Bristol Myers Squibb’s schizophrenia drug Cobenfy was approved on Wednesday by the US Food and Drug Administration (US FDA). It will be available as a two-in-one pill at $1,850 per month. Cobenfy works by activating muscarinic receptors in the gut to suppress the effects of Xanomeline, a drug that is used to treat schizophrenia. It’ll be administered in combination with other drugs.